Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: Role in breast and prostate cancer

Human and Experimental Toxicology

Volumn 25, Issue 7, 2006, Pages 395-404

  Harvey, Philip W ^a   Everett, D J ^a   Springall, C J ^a  

^a UK   (United Kingdom)

Author keywords

Adverse effect; Breast; Cancer; Carcinogenesis; Endocrine disruption; Human; Hyperprolactinaemia; Mammary; Prolactin; Prostate; Rat

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; BROMOCRIPTINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; HALOPERIDOL; PROBASIN; PROLACTIN; PROLACTIN RECEPTOR; RESERPINE; TAMOXIFEN;

AMENORRHEA; ARTICLE; BREAST CANCER; CARCINOGENESIS; CLINICAL TRIAL; DRUG RECEPTOR BINDING; EVIDENCE BASED MEDICINE; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; BREAST NEOPLASMS; CARCINOGENICITY TESTS; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; PROLACTIN; PROSTATIC NEOPLASMS; RECEPTORS, PROLACTIN; RISK ASSESSMENT; RISK FACTORS;

RODENTIA;

EID: 33746514504     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327106ht643oa     Document Type: Article

References (91)

1. Welsch CW, Louks G, Fox D, Brooks C. Enhancement by prolactin of carcinogen induced mammary cancerogenesis in the male rat. Br J Cancer 1975; 32: 427-31.
2. Yokoro K, Nakano M, Ito A, Nagao K, Kodama Y. Role of prolactin in rat mammary carcinogenesis: detection of carcinogenicity of low dose carcinogens and of persisting dormant cancer cells. J Natl Cancer Inst 1977; 58: 1777-83.
3. Drosdowsky M, Edery M, Guggiari M, Montes-Rendon A, Rudali G, Vives C. Inhibition of prolactin-induced mammary cancer in C3Hf (XVII) mice with the trans isomer of bromotriphenylethylene. Cancer Res 1980; 40: 1674-79.
4. Tejwani GA, Gudehithlu KP, Hanissian SH, Gienapp IE, Whitacre CC, Malarkey WB. Facilitation of dimethylbenz[a]anthracene-induced rat mammary carcinogenesis by restraint stress: role of beta-endorphin, prolactin and naltrexone. Carcinogenesis 1991; 12: 637-41.
5. Teller MN, Stock CC, Hellman L, Mountain IM, Bowie M, Rosenberg BJ, et al. Comparative effects of a series of prolactin inhibitors, 17 beta-estradiol and 2 alpha-methyldihydrotestosterone propionate, on growth of 7, 12-dimethylbenz[a]anthracene-induced rat mammary carcinomas. Cancer Res 1977; 37: 3932-38.
6. Nagasawa H, Morii S. Inhibition by early treatment with bromocriptine of spontaneous mammary tumour development in rats with no side effects. Acta Endocrinol 1982; 101: 51-55.
7. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levi R, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59: 1147-54.
8. Gopinath C. Comparative endocrine carcinogenesis. In Harvey PW, Rush KC, Cockburn A eds. Endocrine and hormonal toxicology. John Wiley and Sons, 1999.
9. Greaves P. Histopathology of preclinical toxicity studies: interpretation and relevance in drug safety evaluation. Elsevier Science Publishers B.V., 1990.
10. Kleinberg DL. Prolactin and breast cancer. N Engl J Med 1987; 316: 269-71.
11. Martindale. In Reynolds JEF ed. The extra pharmacopoeia, thirty-first edition. The Royal Pharmaceutical Society, 1996; Reserpine, 942.
12. Otake K, Oiso Y, Mitsuma T, Hirooka Y, Adachi K. Hypothalamic dysfunction in Parkinson's disease patients. Acta Med Hung 1994; 50: 3-13.
13. Bellomo G, Santambrogio L, Fiacconi M, Scarponi AM, Ciuffetti G. Plasma profiles of adrenocorticotrophic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease. J Neurol 1991; 238: 19-22.
14. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 1992; 21: 214-21.
15. Lalonde FM, Myslobodsky M. Are dopamine antagonists a risk factor for breast cancer? An answer from Parkinson's disease. Breast 2003; 12: 280-82.
16. Kwa HG, Cleton F, Wang DY, Bulbrook RD, Bulstrode JC, Hatward JL, et al. A prospective study of plasma prolactin levels and subsequent risk of breast cancer. Int J Cancer 1981; 28: 673-76.
17. Holtkamp W, Nagel GA, Wander HE, Rauschecker HF, von Heyden D. Hyperprolactinaemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer 1984; 34: 323-28.
18. Wang DY, Hampson S, Kwa HG, Moore JW, Bulbrook RD, Fentiman IS, et al. Serum prolactin levels in women with breast cancer and their relationship to survival. Eur J Cancer Clin Oncol 1986; 22: 487-92.
19. Fritze D, Queisser W, Schmid H, Kaufmann M, Massner B, Westerhausen M, et al. Prospective randomized trial concerning hyper- and normoprolactinemia and the use of bromoergocriptine in patients with metastatic breast cancer. Onkologie 1986; 9: 305-12.
20. Bonneterre J, Mauriac L, Weber B, Roche H, Fargeot P, Tubiana-Hulin M, et al. Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial. Eur J Cancer Clin Oncol 1988; 24: 1851-53.
21. Holtkamp W, Nagel GA. Bromocriptine in chemotherapy-resistant, metastatic breast cancer. Results of the GO-MC-BROMO 2/82 AIO study. Onkologie 1988; 11: 121-27.
22. Neumann F. Early indicators for carcinogenesis in sex-hormone-sensitive organs. Mutat Res 1991; 248: 341-56.
23. Gopinath C. The predictive value of pathological findings in animal toxicity studies. J Toxicol Pathol 1995; 8: 89-100.
24. Thordarson G, Galosy S, Gudmundsson GO, Newcomer B, Sridara R, Talamantes F. Interaction of mouse placental lactogens and androgens in regulating progesterone release in cultured mouse luteal cells. Endocrinology 1997; 138: 3236-41.
25. Cargill SL, Medrano JF, Anderson GB. Infertility in a line of mice with the high growth mutation is due to luteal insufficiency resulting from disruption at the hypothalamic-pituitary axis. Biol Eeprod 1999; 61: 282-87.
26. Wakefield LM, Thordarson G, Nieto AI, Shymala G, Galvez JJ, Anver MR, et al. Spontaneous pituitary abnormalities and mammary hyperplasia in FVB/NCr mice: implications for mouse modelling. Comp Med 2003; 53: 424-32.
27. Bogdanffy MS, O'Connor JC, Hansen JF, Gaddamidi V, Van Pelt CS, Green JW, et al. Chronic toxicity and oncogenicity bioassay in rats with the chloro triazine herbicide cyanazine. J Toxicol Environ Health A 2000; 60: 567-86.
28. O'Connor JC, Plowchalk DR, Van Pelt CS, Davis LG, Cook JC. Role of prolactin in chloro-s-triazine rat mammary tumorigenesis. Drug Chem Toxicol 2000; 23: 575-601.
29. Stevens JT, Breckenridge CB, Wetzel L. A risk characterization for atrazine: oncogenicity profile. J Toxicol Environ Health A 1999; 56: 69-109.
30. Cohen SM, Klaunig J, Meek E, Hill RN, Pastoor T, Lehman-McKeeman L, et al. Evaluating the human relevance of chemically induced animal tumors. Toxicol Sci 2004; 78: 181-86.
31. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64: 2291-314.
32. Harvey PW. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments. J Appl Toxicol 2005; 25: 179-83.
33. Vonderhaar BK. Prolactin: the forgotten hormone in breast cancer. Pharmacol Ther 1998; 79: 169-78.
34. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995; 55: 2591-95.
35. Goffin V, Touraine P, Pichard C, Bernichtein S, Kelly P. Should prolactin be reconsidered as a therapeutic target in human breast cancer? Mol Cell Endocrinol 1999; 151: 79-87.
36. Goffin V, Binart N, Touraine P, Kelly PA. Prolactin: the new biology of an old hormone. Annu Rev Physiol 2002; 64: 47-67.
37. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, et al. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol 2000; 26: 540-47.
38. Mershon J, Sall W, Mitchner N, Ben-Jonathan N. Prolactin is a local growth factor in rat mammary tumors. Endocrinology 1995; 136: 3619-23.
39. Gold LS, Slone TH, Manley NB, Bernstein L. Target organs in chronic bioassays of 533 chemical carcinogens. Environ Health Perspect 1991; 93: 233-46.
40. Baldrick P. Carcinogenicity evaluation: comparison of tumor data from dual control groups in Sprague-Dawley rat. Toxicol Pathol 2005; 33: 283-91.
41. Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 2002; 13: 245-50.
42. Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005; 26: 400-22.
43. Beral V; Million Women Study Collaborators. Breast cancer and hormone replacement in the million women study. Lancet 2003; 362: 419-27.
44. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999; 91: 629-34.
45. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004; 64: 6814-19.
46. Vonderhaar BK. Estrogens are not required for prolactin induced growth of MCF-7 human breast cancer cells. Cancer Lett 1989; 47: 105-10.
47. Wiseman H. Tamoxifen: molecular basis of use in cancer treatment and prevention. John Wiley and Sons, 1994.
48. Vonderhaar BK. Prolactin involvement in breast cancer. Endocr Relat Cancer 1999; 6: 389-404.
49. Mujagic Z, Mujagic H. Importance of serum prolactin determination in metastatic breast cancer patients. Croat Med J 2004; 45: 176-80.
50. Gola M, Papi G, Tavernari V, Pesenti M, Ficarra G, Velardo. Mammary carcinoma in a patient with hyperprolactinaemia. Minerva Endocrinol 1987; 22: 107-10.
51. Theodorakis SP, Tedesco VE, Sutherland CM. Breast cancer in a patient with prolactinoma. Surgery 1985; 98: 367-69.
52. Strungs I, Gray RA, Rigby HB, Strutton G. Two case reports of breast carcinoma associated with prolactinoma. Pathology 1997; 29: 320-23.
53. Cueto Ladron de Guevara J, Villalba Moreno J, Garcia Puche JL, Pedraza V. Prolactin and human cancer of the breast. 1. Levels of correlation. Rev Esp Oncol 1985; 32: 439-58.
54. Meng J, Tsai-Morris CH, Dufau ML. Human prolactin receptor variants in breast cancer: low ratio of short forms to the long form human prolactin receptor associated with mammary carcinoma. Cancer Res 2004; 64: 5677-82.
55. Gill S, Peston D, Vonderhaar BK, Shousa S. Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol 2001; 54: 956-60.
56. Das R, Vonherhaar BK. Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia 1997; 2: 29-39.
57. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003; 24: 1-27.
58. Gutzman JH, Rugowski DE, Schroeder MD, Watters JJ, Schuler LA. Multiple kinase cascades mediate prolactin signals to activate protein-1 in breast cancer cells. Mol Endocrinol 2004; 18: 3064-75.
59. Schroeder MD, Symowicz J, Schuler LA. PRL modulates cell cycle regulators in mammary tumour epithelial cells. Mol Endocrinol 2002; 16: 45-57.
60. Favy DA, Rio P, Maurizis JC, Hizel C, Bignon YJ, Bernard-Gallon D. Prolactin dependent up regulation of BRCA1 expression in human breast cancer cell lines. Biochem Biophys Res Commun 1999; 258: 284-91.
61. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 2004; 91: 305-11.
62. Lissoni P, Vaghi M, Villa S, Bodraska A, Cerizza L, Tancini G, et al. Antiprolactinaemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with an LHRH analogue, tamoxifen and the long acting antiprolactin drug carbergoline. Anticancer Res 2003; 23: 733-36.
63. Harvey PW, Darbre P. Endocrine disrupters and human health: could oestrogenic chemicals in body care cosmetics adversely affect breast cancer incidence in women? A review of evidence and call for further research. J Appl Toxicol 2004; 24: 167-76.
64. Leondires MP, Hu ZZ, Dong J, Tsai-Morris CH, Dufau ML. Estradiol stimulates expression of two human prolactin receptor isoforms with alternative exons-1 in T47D breast cancer cells. J Steroid Biochem Mol Biol 2002; 82: 263-68.
65. Murai I, Ben-Jonathan N. Acute stimulation of prolactin release by estradiol: mediation by posterior pituitary. Endocrinology 1990; 126: 3179-84.
66. D'Agata R, Aliffi A, Maugeri A, Vicari E, Gulizia S, Polosa P. Hydrotestolactone lowers serum oestradiol and prolactin levels in normal men: evidence of a role of oestradiol in prolactin secretion. Clin Endocrinol 1982; 17: 495-99.
67. Steinmetz R, Brown NG, Allen DL, Bigsby RM, Ben-Jonathan N. The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo. Endocrinology 1997; 138: 1780-86.
68. De Rosa M, Zarrilli S, Di Sarno A, Milano N, Gaccione M, Boggia B, et al. Hyperprolactinaemia in men: clinical and biochemical features and response to treatment. Endocrine 2003; 20: 75-82.
69. Baranao JLS, Legnani B, Chiauzzi VA, Bertini LM, Suescun MMO, Calvo JC, et al. Effects of prolactin on androgen metabolism in androgen target tissue of immature rats. Endocrinology 1981; 109: 2188-95.
70. Waeber C, Reymond O, Reymond M, Lemarch-Beraud T. Effects of hyper- and hypoprolactinemia on gonadotrophin secretion, rat testicular luteinizing hormone/human chorionic gonadotrophin receptors and testosterone production by isolated Leydig cells. Biol Reprod 1983; 28: 167-77.
71. Slonim AE, Glick AD, Island DP, Kasselberg AG. Hyperprolactinaemia associated with advanced puberty in a male. J Pediatr 1982; 101: 236-39.
72. Chowdhury M, Kabir SN, Pal AK, Pakrashi A. Modulation of luteinizing hormone receptors: effect of an inhibitor of prolactin secretion, p-coumaric acid. J Endocrinol 1983; 98: 307-11.
73. Hussein MO, Zipf WB. Characteristics of prolactin-modulated LH induction of LH/hCG receptors. Transient inhibition of receptor induction following prolactin exposure. J Androl 1987; 8: 388-92.
74. Amador AG, Bartke A. Effects of in vivo and in vitro exposure to bromocriptine on testicular LH receptors and in vitro testosterone production in Syrian hamsters. Rev Esp Fisiol 1991; 47: 121-27.
75. Maran RR, Arunakaran J, Aruldhas MM. Prolactin and Leydig cells: biphasic effects of prolactin on LH-, T3- and GH-induced testosterone/oestradiol secretion by Leydig cells in pubertal rats. Int J Androl 2001; 24: 48-55.
76. Takeyama M, Nagareda T, Takatsuka D, Namiki M, Koizumi K, Aono T, et al. Stimulatory effect of prolactin on luteinizing hormone-induced testicular 5 alpha-reductase activity in hypophysectomized adult rats. Endocrinology 1986; 118: 2268-75.
77. Soronen P, Laiti M, Torn S, Harkonen P, Patrikainen L, Li Y, et al. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 281-86.
78. Burnstein KL. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 2005; 95: 657-69.
79. Damber JE. Endocrine therapy in prostate cancer. Acta Oncol 2005; 44: 605-609.
80. Berthelet E, Pickles T, Lee KW, Liu M, Truong PT; Prostate Cancer Outcomes Initiative. Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL. Int J Radiat Oncol Biol Phys 2005; 63: 781-87.
81. Ruffion A, Al-Sakkaf KA, Brown BL, Eaton CL, Hamdy FC, Dobson PR. The survival effect of prolactin on PC3 prostate cancer cells. Eur Urol 2003; 43: 301-308.
82. Ahonen TJ, Harkonen PL, Laine J, Rui H, Matrikainen PM, Nevalainen MT. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 1999; 140: 5412-21.
83. Van Coppenolle F, Slomianny C, Carpentier F, Le Bourhis X, Ahidouch A, Croix D, et al. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am J Physiol Endocrinol Metab 2001; 280: E120-29.
84. Dillner K, Kindblom J, Flores-Morales A, Shao R, Tornell J, Norstedt G, et al. Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. Endocrinology 2003; 144: 4955-66.
85. Nakamura A, Shirai T, Ogawa K, Wada S, Fujimoto NA, Ito A, et al. Promoting action of prolactin released from a grafted transplantable pituitary tumour (MtT/F84) on rat prostate carcinogenesis. Cancer Lett 1990; 53: 151-57.
86. Robertson FG, Harris J, Naylor MJ, Oakes SR, Kindblom J, Dillner K, et al. Prostate development and carcinogenesis in prolactin receptor knockout mice. Endocrinology 2003; 144: 3196-205.
87. Lissoni P, Bignami A, Frontini L, Manganini V, Dapretto E, Gardani GS, et al. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer. Int J Biol Mark 2005; 20: 123-25.
88. Lissoni P, Mandala M, Giani L, Malugani F, Secondino S, Zonato S, et al. Efficacy of bromocriptine in the treatment of metastatic breast cancer and prostate cancer related hyperprolactinaemia. Neurol Endocrinol Lett 2000; 21: 405-408.
89. Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, et al. Plasma prolactin and prostate cancer risk: a prospective study. Int J Cancer 2001; 92: 463-65.
90. Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, et al. Antitumour activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 2003; 63: 386-93.
91. Asa SL. Transgenic and knockout mouse models clarify pituitary development, function and disease. Brain Pathol 2001; 11: 370-83.